{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:00:46Z","timestamp":1762423246001,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000},"content-version":"vor","delay-in-days":820,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["apjon.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Oncology Nursing"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.4103\/apjon.apjon_14_19","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T06:04:00Z","timestamp":1559196240000},"page":"318-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review"],"prefix":"10.1016","volume":"6","author":[{"given":"Deborah","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Kanzawa-Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Knoerl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwen","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen M","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4103\/apjon.apjon_14_19_bib1","doi-asserted-by":"crossref","unstructured":"Meyer-Rosberg K, Kvarnstr\u00f6m A, Kinnman E, Gordh T, Nordfors LO, Kristofferson A. Peripheral neuropathic pain \u2013 A multidimensional burden for patients. Eur J Pain 379\u201389.","DOI":"10.1053\/eujp.2001.0259"},{"key":"10.4103\/apjon.apjon_14_19_bib2","doi-asserted-by":"crossref","unstructured":"Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer 2261\u20139.","DOI":"10.1007\/s00520-014-2255-7"},{"key":"10.4103\/apjon.apjon_14_19_bib3","doi-asserted-by":"crossref","unstructured":"Bakitas MA. Background noise: The experience of chemotherapy-induced peripheral neuropathy. Nurs Res 323\u201331.","DOI":"10.1097\/01.NNR.0000289503.22414.79"},{"key":"10.4103\/apjon.apjon_14_19_bib4","doi-asserted-by":"crossref","unstructured":"Sasane M, Tencer T, Beusterien K. PCN63 review of the economic impact of chemotherapy induced peripheral neuropathy. Value Health A268.","DOI":"10.1016\/S1098-3015(10)74314-X"},{"key":"10.4103\/apjon.apjon_14_19_bib5","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","author":"Hershman","year":"1941","journal-title":"J Clin Oncol"},{"key":"10.4103\/apjon.apjon_14_19_bib6","doi-asserted-by":"crossref","unstructured":"Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA 1359\u201367.","DOI":"10.1001\/jama.2013.2813"},{"key":"10.4103\/apjon.apjon_14_19_bib7","doi-asserted-by":"crossref","unstructured":"Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2627\u201333.","DOI":"10.1200\/JCO.2012.44.8738"},{"key":"10.4103\/apjon.apjon_14_19_bib8","doi-asserted-by":"crossref","unstructured":"Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance). J Clin Oncol 997\u20131005.","DOI":"10.1200\/JCO.2013.52.0536"},{"key":"10.4103\/apjon.apjon_14_19_bib9","doi-asserted-by":"crossref","unstructured":"Arrieta \u00d3, Hern\u00e1ndez-Pedro N, Fern\u00e1ndez-Gonz\u00e1lez-Arag\u00f3n MC, Saavedra-P\u00e9rez D, Campos-Parra AD, R\u00edos-Trejo M\u00c1, et al. Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology 987\u201395.","DOI":"10.1212\/WNL.0b013e31822e045c"},{"key":"10.4103\/apjon.apjon_14_19_bib10","doi-asserted-by":"crossref","unstructured":"Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, et al. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 161\u20136.","DOI":"10.1007\/s002800050723"},{"key":"10.4103\/apjon.apjon_14_19_bib11","doi-asserted-by":"crossref","unstructured":"Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 490\u20136.","DOI":"10.1200\/JCO.1995.13.2.490"},{"key":"10.4103\/apjon.apjon_14_19_bib12","doi-asserted-by":"crossref","unstructured":"Flannelly KJ, Flannelly LT, Jankowski KR. Threats to the internal validity of experimental and quasi-experimental research in healthcare. J Health Care Chaplain 107\u201330.","DOI":"10.1080\/08854726.2017.1421019"},{"key":"10.4103\/apjon.apjon_14_19_bib13","doi-asserted-by":"crossref","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 777\u201384.","DOI":"10.7326\/M14-2385"},{"year":"2014","series-title":"New JBI Levels of Evidence","author":"The Joanna Briggs Institute","key":"10.4103\/apjon.apjon_14_19_bib14"},{"key":"10.4103\/apjon.apjon_14_19_bib15","doi-asserted-by":"crossref","unstructured":"Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial. Support Care Cancer 1223\u201331.","DOI":"10.1007\/s00520-013-2075-1"},{"key":"10.4103\/apjon.apjon_14_19_bib16","doi-asserted-by":"crossref","unstructured":"Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 2101\u201312.","DOI":"10.1200\/JCO.1996.14.7.2101"},{"key":"10.4103\/apjon.apjon_14_19_bib17","doi-asserted-by":"crossref","unstructured":"Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 1086\u201393.","DOI":"10.1093\/annonc\/mdg301"},{"key":"10.4103\/apjon.apjon_14_19_bib18","doi-asserted-by":"crossref","unstructured":"Gobran NS. Role of calcium and magnesium infusion in prevention of oxaliplatin neurotoxicity.A phase III trial. Chin Ger J Clin Oncol 232\u20136.","DOI":"10.1007\/s10330-013-1161-7"},{"key":"10.4103\/apjon.apjon_14_19_bib19","doi-asserted-by":"crossref","unstructured":"Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol 4010.","DOI":"10.1200\/jco.2008.26.15_suppl.4010"},{"key":"10.4103\/apjon.apjon_14_19_bib20","doi-asserted-by":"crossref","unstructured":"Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 421\u20137.","DOI":"10.1200\/JCO.2010.31.5911"},{"key":"10.4103\/apjon.apjon_14_19_bib21","doi-asserted-by":"crossref","unstructured":"Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 4028\u20139.","DOI":"10.1200\/JCO.2007.13.5251"},{"key":"10.4103\/apjon.apjon_14_19_bib22","doi-asserted-by":"crossref","unstructured":"Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. Int J Clin Oncol 82\u20137.","DOI":"10.1007\/s10147-009-0015-3"},{"key":"10.4103\/apjon.apjon_14_19_bib23","doi-asserted-by":"crossref","unstructured":"Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 3478\u201383.","DOI":"10.1200\/JCO.2002.07.061"},{"key":"10.4103\/apjon.apjon_14_19_bib24","doi-asserted-by":"crossref","unstructured":"Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. J Clin Oncol 26\u201332.","DOI":"10.1200\/JCO.1995.13.1.26"},{"key":"10.4103\/apjon.apjon_14_19_bib25","doi-asserted-by":"crossref","unstructured":"Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al. : Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin; 1997. p. 69\u201373.","DOI":"10.1023\/A:1008211226339"},{"key":"10.4103\/apjon.apjon_14_19_bib26","doi-asserted-by":"crossref","unstructured":"Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, et al. North central cancer treatment group\/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel\/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study. Cancer 1890\u20137.","DOI":"10.1002\/cncr.28654"},{"key":"10.4103\/apjon.apjon_14_19_bib27","doi-asserted-by":"crossref","unstructured":"Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, et al. Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): A placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 767\u201375.","DOI":"10.1007\/s10147-015-0784-9"},{"key":"10.4103\/apjon.apjon_14_19_bib28","doi-asserted-by":"crossref","unstructured":"Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, et al. MC11C4: A pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer 1071\u20138.","DOI":"10.1007\/s00520-015-2876-5"},{"key":"10.4103\/apjon.apjon_14_19_bib29","doi-asserted-by":"crossref","unstructured":"Pace A, Giannarelli D, Gali\u00e8 E, Savarese A, Carpano S, Della Giulia M, et al. Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial. Neurology 762\u20136.","DOI":"10.1212\/WNL.0b013e3181d5279e"},{"key":"10.4103\/apjon.apjon_14_19_bib30","doi-asserted-by":"crossref","unstructured":"Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial. Support Care Cancer 1769\u201377.","DOI":"10.1007\/s00520-010-1018-3"},{"key":"10.4103\/apjon.apjon_14_19_bib31","doi-asserted-by":"crossref","unstructured":"Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2110\u20138.","DOI":"10.1002\/cncr.23008"},{"key":"10.4103\/apjon.apjon_14_19_bib32","unstructured":"Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev CD007938."},{"key":"10.4103\/apjon.apjon_14_19_bib33","doi-asserted-by":"crossref","unstructured":"Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2802\u20138.","DOI":"10.1002\/cncr.23482"},{"key":"10.4103\/apjon.apjon_14_19_bib34","doi-asserted-by":"crossref","unstructured":"Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 195\u2013203.","DOI":"10.1016\/S0304-3959(02)00047-7"},{"key":"10.4103\/apjon.apjon_14_19_bib35","doi-asserted-by":"crossref","unstructured":"Harvey BH, Slabbert FN. New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol 503\u201316.","DOI":"10.1002\/hup.2429"},{"key":"10.4103\/apjon.apjon_14_19_bib36","unstructured":"Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 1148\u201358."},{"key":"10.4103\/apjon.apjon_14_19_bib37","doi-asserted-by":"crossref","unstructured":"Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. Adouble-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 833\u201341.","DOI":"10.1007\/s00520-010-0911-0"},{"key":"10.4103\/apjon.apjon_14_19_bib38","doi-asserted-by":"crossref","unstructured":"Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, et al. Aphase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer 1807\u201314.","DOI":"10.1007\/s00520-014-2158-7"},{"key":"10.4103\/apjon.apjon_14_19_bib39","doi-asserted-by":"crossref","unstructured":"Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindstr\u00f6m T, Thorell LH, et al. Acomparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 313\u201323.","DOI":"10.1097\/00002508-199712000-00009"},{"key":"10.4103\/apjon.apjon_14_19_bib40","doi-asserted-by":"crossref","unstructured":"Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 200\u20135.","DOI":"10.1093\/annonc\/mdr045"},{"key":"10.4103\/apjon.apjon_14_19_bib41","doi-asserted-by":"crossref","unstructured":"Grothey A, Qin R, Dakhil S, Fehrenbacher L, Stella P, Atherton P, et al. O-0032 phase III randomized, placebo(PL)-Controlled, double-blind study of intravenous calcium\/magnesium (CAMG) to prevent oxaliplatin-induced sensory Neurotoxicity (SNT), N08CB: An alliance for clinical trials in oncology study1. Ann Oncol iv24.","DOI":"10.1093\/annonc\/mdt201.32"},{"key":"10.4103\/apjon.apjon_14_19_bib42","doi-asserted-by":"crossref","unstructured":"Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol 51\u201377.","DOI":"10.1016\/j.critrevonc.2011.04.012"},{"key":"10.4103\/apjon.apjon_14_19_bib43","doi-asserted-by":"crossref","unstructured":"Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): What we need and what we know. J Peripher Nerv Syst 66\u201376.","DOI":"10.1111\/jns5.12073"},{"key":"10.4103\/apjon.apjon_14_19_bib44","doi-asserted-by":"crossref","unstructured":"Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL, et al. National cancer institute-supported chemotherapy-induced peripheral neuropathy trials: Outcomes and lessons. Support Care Cancer 1439\u201347.","DOI":"10.1007\/s00520-015-3063-4"},{"key":"10.4103\/apjon.apjon_14_19_bib45","unstructured":"Smith EM, Knoerl R, Yang JJ, Kanzawa-Lee G, Lee D, Bridges CM, et al. In search of a gold standard patient-reported outcome measure for use in chemotherapy- induced peripheral neuropathy clinical trials. Cancer Control 1073274818756608."},{"key":"10.4103\/apjon.apjon_14_19_bib46","doi-asserted-by":"crossref","unstructured":"Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. Eur J Cancer 479\u201394.","DOI":"10.1016\/j.ejca.2009.12.008"},{"key":"10.4103\/apjon.apjon_14_19_bib47","doi-asserted-by":"crossref","unstructured":"Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, et al. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer 1071\u201380.","DOI":"10.1007\/s00520-008-0550-x"},{"key":"10.4103\/apjon.apjon_14_19_bib48","doi-asserted-by":"crossref","unstructured":"Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK, et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 739\u201344.","DOI":"10.1023\/A:1008344507482"},{"key":"10.4103\/apjon.apjon_14_19_bib49","doi-asserted-by":"crossref","unstructured":"Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 1297\u2013300.","DOI":"10.1212\/01.WNL.0000092015.03923.19"},{"key":"10.4103\/apjon.apjon_14_19_bib50","doi-asserted-by":"crossref","unstructured":"Smith EM, Beck SL, Cohen J. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 96\u2013102.","DOI":"10.1188\/08.ONF.96-102"},{"key":"10.4103\/apjon.apjon_14_19_bib51","doi-asserted-by":"crossref","unstructured":"Gewandter JS, Dworkin RH, Finnerup NB, Mohile NA. Painful chemotherapy-induced peripheral neuropathy: Lack of treatment efficacy or the wrong clinical trial methodology. Pain 30\u20133.","DOI":"10.1097\/j.pain.0000000000000653"},{"key":"10.4103\/apjon.apjon_14_19_bib52","doi-asserted-by":"crossref","unstructured":"Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, et al. Psychometric evaluation of the functional assessment of cancer therapy\/Gynecologic oncology group-neurotoxicity (Fact\/GOG-ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 741\u20138.","DOI":"10.1111\/j.1525-1438.2003.13603.x"},{"key":"10.4103\/apjon.apjon_14_19_bib53","doi-asserted-by":"crossref","unstructured":"Atkinson TM, Mendoza TR, Sit L, Passik S, Scher HI, Cleeland C, et al. The brief pain inventory and its \u201cpain at its worst in the last 24 hours\u201d item: Clinical trial endpoint considerations. Pain Med 337\u201346.","DOI":"10.1111\/j.1526-4637.2009.00774.x"},{"key":"10.4103\/apjon.apjon_14_19_bib54","doi-asserted-by":"crossref","unstructured":"Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 15\u201349.","DOI":"10.1053\/j.seminoncol.2005.12.010"},{"key":"10.4103\/apjon.apjon_14_19_bib55","doi-asserted-by":"crossref","unstructured":"Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: Discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med 178\u201388.","DOI":"10.1007\/s11606-008-0877-5"}],"container-title":["Asia-Pacific Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562521001864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562521001864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:57:32Z","timestamp":1762423052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2347562521001864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2347562521001864"],"URL":"https:\/\/doi.org\/10.4103\/apjon.apjon_14_19","relation":{},"ISSN":["2347-5625"],"issn-type":[{"type":"print","value":"2347-5625"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4103\/apjon.apjon_14_19","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Ann & Joshua Medical Publishing Co. Ltd.","name":"copyright","label":"Copyright"}]}}